Advertisement

ASCO GU 2024: Cabozantinib and Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Posted: 02/26/2024 | By: Chase Doyle

At the 2024 ASCO Genitourinary Cancers Symposium, researchers presented results of CONTACT-2, which compared the combination of cabozantinib plus atezolizumab to hormonal therapy in patients with metastatic castration-resistant prostate cancer with extrapelvic nodal or visceral metastasis (Abstract 18).

Question 1 of 5

What was the primary endpoint of the phase III CONTACT-2 study?

Choose 1

A
Overall survival in the first 400 randomly assigned patients
B
Radiographic progression–free survival by blinded independent radiology committee per RECIST 1.1 in the first 400 randomly assigned patients, and overall survival in all randomly assigned patients
C
Overall response rate by RECIST 1.1 per blinded independent radiology committee
D
Duration of response

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage